OB/GYN Clinical Alert – September 1, 2023
September 1, 2023
View Archives Issues
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.
Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) for patients at high risk of breast and ovarian cancer led to decreased cancer-related distress, unaffected health-related quality of life, poorer body image after RRM, and decreased sexual function and increased menopause symptoms after RRSO.
Therapy for gestational diabetes diagnosed before 20 weeks of pregnancy was associated with a slightly decreased frequency of a composite of unfavorable neonatal outcomes compared to deferred treatment or no therapy. No significant changes were demonstrated for pregnancy-related hypertension or neonatal lean body mass between the two groups.
In this retrospective cohort study, 233 individuals who conceived with a copper intrauterine device (IUD) in place were followed. There were 44 ectopic pregnancies, 31 non-viable intrauterine pregnancies, and 158 viable intrauterine pregnancies. Of the viable pregnancies, 137 patients continued the pregnancy and, of these, 54 had the IUD removed. Those who underwent IUD removal had a lower rate of pregnancy loss (33%) compared to those who retained the IUD (61.4%).